Steno Diabetes Center Copenhagen
Herlev, 2730, Denmark
NCT Number: NCT06832059
The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Herlev, 2730, Denmark
In recent decades, there has been a significant rise in the development and use of glucose lowering drugs aimed at improving glycemic control in individuals with type 2 diabetes (T2D). Despite medical advancements, more than one-third of the danish population with T2D have a hemoglobin A1c (HbA1c) exceeding the recommended thresholds. One limiting factor in supporting individuals achieve their glycaemic target may be driven by substantial postprandial increases in plasma glucose levels, which is influenced by the quantity and type of carbohydrates in meals, underscoring the critical role of dietary interventions as an integral component of T2D management.
Recent studies have demonstrated that the use of continuous glucose monitors (CGMs), which allow individuals to track their glucose profiles continuously throughout the day, improves glycemic control in T2D patients. However, these studies often exclude dietary interventions, which could potentially yield greater improvements in blood glucose regulation.
Nutritional research in recent years has focused on dietary patterns such as low-fat diets, the paleo diet, and vegan diets. Nevertheless, these studies have not sufficiently addressed individualized dietary adjustments to mitigate postprandial glucose excursions, despite their substantial importance for glycemic control.
Several clinical studies have revealed significant inter-individual variations in glycemic responses to identical standardized meals, highlighting the necessity of a personalized approach to dietary recommendations, particularly with a focus on carbohydrate intake.
The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l
Time frame: 12 weeks after baseline
Participants will be invited to a workshop to evaluate the intervention and its components. Procedures from fidelity testing will be applied in the evaluation. These specific topics will be evaluated:
o Is the design appropriate? E.g., number of visits, CGM use, dietetic feedback?
o E.g., how many participated, recruitment methods, sample diversity?
Time frame: Measured at baseline and after 12 weeks
Assessed from blood samples
Time frame: Measured at baseline and after 12 weeks
Time spent in time in range 3.9 mmol/l - 10.0 mmol/l from CGM data
Time frame: Measured at baseline and after 12 weeks
Time spent in time above range 10.1-13.9 mmol/l from CGM data
Time frame: Measured at baseline and after 12 weeks
Time spent in time below range <3.9 mmol/l from from CGM data
Time frame: Measured at baseline and after 12 weeks
Percentage coefficient of variation in glucose differences
Time frame: Measured at baseline and after 12 weeks
Estimated HbA1c (14-days average of the CGM data)
Time frame: Measured at baseline and after 12 weeks
Calculated from body weight (kg) and height (m).
Time frame: Measured at baseline and after 12 weeks
Measured on a digital scale
Time frame: Measured at baseline and after 12 weeks
Measured using tape measure.
Time frame: Measured at baseline and after 12 weeks
Measured using tape measure
Time frame: Measured at baseline and after 12 weeks
Measured under resting
Time frame: Measured at baseline and after 12 weeks
Measured under resting
Time frame: Measured at baseline and after 12 weeks
Assessed from the Problem Areas in Diabetes Scale comprising of twenty emotional-distress questions. Each item can be rated from 0 to 5.
Time frame: Measured at baseline and after 12 weeks
Assessed from the questionnaire Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Time frame: Measured at baseline and after 12 weeks
Dietary intake (total energy intake and macronutrient composition based on 3-days' diet records)
Time frame: Measured at baseline and after 12 weeks
Medication status, change in doses or discontinuation of medicine
Time frame: Baseline
Assesed fromt the BIG FIVE Inventory questionnaire (BFI-44). Comprising of 44 items.
Time frame: Measured at baseline and after 12 weeks
Physical activity levels measured by X3 accelerometers
Steno Diabetes Center Copenhagen
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05710900
Diabetes Mellitus, Diabetes Mellitus, Type 2
Kelowna, British Columbia, Canada
View Trial DetailsNCT07400653
Body Weight, Diabetes Mellitus
Anaheim, California, United States
View Trial DetailsNCT05040087
Diabetes Mellitus, Diabetes Mellitus, Type 2
Decatur, Georgia, United States
View Trial DetailsNCT05360056
Diabetes Mellitus, Diabetes Mellitus, Type 2
Columbus, Ohio, United States
View Trial Details